Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (441-450 of 583) with videos related to

Pageof 59
Sort By:
Cancer|December 12, 1997
Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in LeukemiaC D Bloomfield, C Shuma, L Regal, et al.
Oncotarget|August 13, 2016
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Ramasamy Santhanam, et al.
Blood|August 27, 2013
Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemiaLiat Goldberg, Marloes R Tijssen, Yehudit Birger, et al.
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2020
Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/<i>KMT2A</i>Marius Bill, Krzysztof Mrózek, Jessica Kohlschmidt, et al.
Blood|February 21, 2004
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemiaMikkael A Sekeres, Bercedis Peterson, Richard K Dodge, et al.
Haematologica|June 12, 2013
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germlineJason H Mendler, Kati Maharry, Heiko Becker, et al.
Blood|May 23, 2001
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)M R Baer, C C Stewart, R K Dodge, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognosesH E Campbell, D Epstein, D Bloomfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B StudyK Mrózek, T W Prior, C Edwards, et al.
Pageof 59

Showing results (441-450 of 583) with videos related to

Sort By:
Pageof 59
Cancer|December 12, 1997
Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in LeukemiaC D Bloomfield, C Shuma, L Regal, et al.
Oncotarget|August 13, 2016
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Ramasamy Santhanam, et al.
Blood|August 27, 2013
Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemiaLiat Goldberg, Marloes R Tijssen, Yehudit Birger, et al.
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2020
Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/<i>KMT2A</i>Marius Bill, Krzysztof Mrózek, Jessica Kohlschmidt, et al.
Blood|February 21, 2004
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemiaMikkael A Sekeres, Bercedis Peterson, Richard K Dodge, et al.
Haematologica|June 12, 2013
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germlineJason H Mendler, Kati Maharry, Heiko Becker, et al.
Blood|May 23, 2001
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)M R Baer, C C Stewart, R K Dodge, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognosesH E Campbell, D Epstein, D Bloomfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B StudyK Mrózek, T W Prior, C Edwards, et al.
Pageof 59